Abstract: A class of phosphorus containing polycyclic compounds of general formula I, of general formula I? or of general formula I?, wherein B1, B2, R1, R2, R1?, X1, X2, Y1, Y2, BL1, BL2, Z1, and Z2 are defined herein, that may be useful as modulators of type I interferon production, specifically as STING modulating agents, are provided. Also, provided are use of such compounds.
Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.
Type:
Grant
Filed:
July 26, 2018
Date of Patent:
January 7, 2020
Assignees:
The University of British Columbia, Centre for Drug Research and Development
Inventors:
Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
Abstract: An aqueous gel mask composition is disclosed including a plurality of sodium alginates constituting, by weight, between 2.2% to 4.5% of the aqueous gel mask composition, and water, wherein the aqueous gel mask composition is reactive with an activator to form a continuous film. An aqueous gel mask kit is disclosed including the aqueous gel mask composition and an activator.
Abstract: The present invention provides a method for preparing regenerated cellulose fibers having anti-bacteria, anti-mite and anti-mould functions from a fennel extract, a Litsea cubeba extract, and a thyme essential oil. The present invention also relates to the use of the regenerated cellulose fiber prepared by the above method in the field of anti-bacteria, anti-mite and mildew-resistant fabrics. The invention solves the technical defect that regenerated cellulose fibers have a single function and has poor anti-mite and anti-mould effects in the prior art.
Abstract: The invention relates to a process for producing food ingredients from Stevia rebaudiana plant and their use in food products, beverages and other consumables. Obtained compositions are useful as flavors, sweeteners, antioxidants, and other functional ingredients.
Abstract: Methods and compositions of reducing or eliminating the symptoms of withdrawal from drug or alcohol in drug or alcohol-dependent persons, while restoring the patient to nutritional health. The methods including parenteral administration of solutions containing high doses of ascorbic acid, including the serial administration of doses of ascorbic acid that differ in concentration by at least 10 fold (by weight). Compositions of the invention comprise at least about 20% (w),or at least about 25% (w), or at least about 30% (w), or at least about 35% (w), or at least about 38% (w) of ascorbic acid and a local anesthetic.
Abstract: This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.
Type:
Grant
Filed:
September 5, 2016
Date of Patent:
November 19, 2019
Assignee:
University of the Witwatersrand, Johannesburg
Inventors:
Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Poornima Ramburrun
Abstract: The present invention relates to a calpain activation inhibitor, muscle damage inhibitor, muscle endurance improver or muscle fatigue recovery agent containing an ?-methylsulfinylalkyl isothiocyanate or physiologically acceptable salt thereof as an active ingredient, foods or beverages, pharmaceuticals or cosmetics containing the same, a pharmaceutical for the prophylaxis and/or treatment of diseases related to muscle damage or diseases related to reduced muscle mass caused by aging, and a method for the use thereof.
Abstract: Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
Abstract: The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
October 8, 2019
Assignee:
Novartis AG
Inventors:
Emmanuelle di Tomaso, Marie-Caroline Germa, Cristian Massacesi, Christine Fritsch, Christian René Schnell, Ranjana Tavorath
Abstract: A compound containing one mole of a free fatty acid and one mole of the ammonium salt of the fatty acid and represented by the structural formula (I): CH3(CH2)xCOOH.CH3(CH2)xCOO?NH4+??(I) wherein x is 6, 7 or 8. Bacterial contaminated surfaces may be disinfected or bacteria removed from a bacterial contaminated surface by applying onto the surface a bactericidally effective amount of the compound.
Abstract: The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Stevia rebaudiana Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are useful as non-caloric sweeteners or in combination with sugar or high intensity sweeteners in edible and chewable compositions such as beverages, confectionaries, bakery products, chewing gums and the like.
Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
September 24, 2019
Assignee:
Epizyme, Inc.
Inventors:
Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
September 17, 2019
Assignee:
RHIZEN PHARMACEUTICALS SA
Inventors:
Swaroop K. Vakkalanka, Srikant Viswanadha
Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
Abstract: The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2?-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.
Abstract: The present invention is concerned with the use of the natural product Ilicicolin H as an agricultural fungicide, compositions comprising Ilicicolin H, and the use of such compositions to treat, control or prevent fungal infection in agricultural products.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
September 17, 2019
Assignee:
Agrobiologics LLC
Inventors:
Jon D. Polishook, Daniel P. Ring, Sheo B. Singh, James Frederic Walter
Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.